Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Find generic entry opportunities
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Process for preparing 1-[2-(2,4-dimethylphenysulfanyl)-pheny]piperazine or pharmaceutically acceptable salt thereof|
|Abstract:||This disclosure relates to a process for the preparation of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a salt thereof. The process includes reacting compound II with compound III and compound IV ##STR00001## in the presence of a solvent, a base and a palladium catalyst. R, R', X.sub.1, and X.sub.2 in the formulas above are defined in the Specification.|
|Inventor(s):||Faldt; Andre (Ishoj, DK), Ringgaard; Lone Munch (Copenhagen, DK), Mealy; Michael J. (Lejre, DK), Rock; Michael Harold (Hvidovre, DK), Brodersen; Jorgen (Holbaek, DK), Jorgensen; Morten (Bagsvaerd, DK)|
|Assignee:||H. Lundbeck A/S (Copenhagen-Valby, DK)|
|Filing Date:||Aug 29, 2014|
|Claims:||1. A process for the preparation of ##STR00017## or a salt thereof, the process comprising reacting compound II ##STR00018## wherein R' represents hydrogen or a mono-valent metal ion, with compound III ##STR00019## wherein X.sub.1 represents Br and X.sub.2 represents I, and compound IV ##STR00020## wherein R represents hydrogen, in the presence of a solvent, a base and a palladium catalyst consisting of a palladium source and a phosphine ligand at a temperature between 60.degree. C. and 130.degree. C. |
2. The process according to claim 1, wherein compound II and compound III are reacted in a first reaction, and wherein the reaction product ##STR00021## for said first reaction is optionally isolated and purified, followed by a subsequent reaction with the compound IV.
3. The process according to claim 1, wherein compound II, compound III and compound IV are mixed together at the start of the process.
4. The process according to claim 1, wherein said solvent is an aprotic solvent.
5. The process according to claim 1, wherein the solvent is selected from the group consisting of toluene, xylene, triethyl amine, tributyl amine, dioxin and N-methylpyrrolidone.
6. The process according to claim 5, wherein the solvent is toluene.
7. The process according to claim 1, wherein the palladium source is selected from the group consisting of Pddba.sub.2, Pd(OAc).sub.2 and Pd.sub.2dba.sub.3.
8. The process according to claim 7, wherein said palladium source is Pddba.sub.2 or Pd.sub.2dba.sub.3.
9. The process according to claim 1, wherein said phosphine ligand is selected from the group consisting of 2,2'-bis-diphenylphosphanyl-[1,1']binaphtalenyl (rac-BINAP), 1,1'-bis(diphenylphosphino)ferrocene (DPPF), bis-(2-diphenylphosphinophenyl)ether (DPEphos), tri-t-butyl phosphine (Fu's salt), biphenyl-2-yl-di-t-butyl-phosphine, biphenyl-2-yl-dicyclohexyl-phosphine, (2'-dicyclohexylphosphanyl-biphenyl-2-yl)-dimethyl-amine, [2'-(di-t-butyl-phosphanyl)-biphenyl-2-yl]-dimethyl-amine, and dicyclohexyl-(2',4',6'-tri-propyl-biphenyl-2-yl)-phosphane.
10. The process according to claim 9, wherein said phosphine ligand is rac-BINAP.
11. The process according to claim 1, wherein said base is selected from the group consisting of NaO(t-Bu), KO(t-Bu), Cs.sub.2CO.sub.3, DBU and DABCO.
12. The process according to claim 11, wherein said base is NaO(t-Bu).
13. The process according to claim 1, wherein R' is hydrogen.
14. The process according to claim 1, wherein the temperature is between 80.degree. C. and 120.degree. C.
15. The process according to claim 3, comprising the steps of a. Dissolving or dispersing 1-1.5 equivalents of compounds II, III, and IV in toluene to obtain mixture A; b. Adding 1-2 mole-% of Pddba.sub.2 and 1-2 mole-% of rac-BINAP together with 2-3 equivalents of NaO(t-Bu) to mixture A to obtain mixture B, which is heated to around 100.degree. C. until compound II and III are fully converted; c. Increasing the temperature of the mixture obtained in step b to around 120.degree. C. until compound IV is fully converted.
16. The process according to claim 1, further comprising an additional step of reacting aqueous HBr with the product ##STR00022## said product optionally being in a purified form, to obtain the hydrobromic acid salt of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine.
17. The process of claim 16, further comprises precipitating the hydrobromic acid salt after 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine is reacted with the aqueous HBr, wherein the hydrobromic acid salt is crystalline.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.